ReviewOncoimmunology2023
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6
Abstract readReview
In one paragraph
Review in Oncoimmunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Advances in proton therapy technology and global clinical applications.Frontiers in oncology · 2026Review
- Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.Oncoimmunology · 2025Article
- Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.Molecular cancer · 2025Review
- Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor-positive mammary carcinogenesis.Journal of the National Cancer Institute · 2025Article
- Radical hemithorax radiotherapy induces an increase in circulating PD-1Frontiers in immunology · 2025Article
- Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Response of Spontaneous Oral Tumors in Canine Cancer Patients Treated with Stereotactic Body Radiation Therapy (SBRT).Radiation research · 2024Article
- Biological Insights and Radiation-Immuno-Oncology Developments in Primary and Secondary Brain Tumors.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Fabiana GregucciDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-9947-9650
Sheila SpadaDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0001-8644-2237
Mary Helen Barcellos-HoffDepartment of Radiation Oncology, School of Medicine, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-5994-9558
Nina BhardwajPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID https://orcid.org/0000-0003-1865-4187
Charleen Chan Wah HakTranslational Immunotherapy Team, The Institute of Cancer Research, London, UK.ORCID https://orcid.org/0000-0002-6386-5699
Alba FiorentinoDepartment of Radiation Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti, Bari, Italy.ORCID https://orcid.org/0000-0003-4201-5852
Chandan GuhaDepartment of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA.ORCID https://orcid.org/0000-0002-1906-2186
Monica L GuzmanDivision of Hematology/Oncology, Department of Medicine, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Kevin HarringtonThe Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute for Health Research Biomedical Research Centre, London, UK.ORCID https://orcid.org/0000-0002-6014-348X
Fernanda G HerreraCentre Hospitalier Universitaire Vaudois, University of Lausanne and Ludwig Institute for Cancer Research at the Agora Cancer Research Center, Lausanne, Switzerland.ORCID https://orcid.org/0000-0001-7984-0472
Jamie HoneychurchDivision of Cancer Sciences, University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0001-6938-0839
Theodore HongDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0001-8481-6581
Lorea IturriInstitut Curie, Université PSL, CNRS UMR3347, INSERM U1021, Signalisation Radiobiologie et Cancer, Orsay, France.ORCID https://orcid.org/0000-0002-7911-3117
Elisabeth JaffeeJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Sana D KaramDepartment of Radiation Oncology, University of Colorado, Aurora, CO, USA.ORCID https://orcid.org/0000-0003-1676-5967
Simon R V KnottDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Constantinos KoumenisDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0001-5945-4726
David LydenChildren's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0003-0193-4131
Ariel E MarciscanoDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0001-8838-2127
Alan MelcherDivision of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.ORCID https://orcid.org/0000-0002-2042-3380
Michele MondiniDepartment of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.ORCID https://orcid.org/0000-0001-5803-0083
Anna MondinoDivision of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID https://orcid.org/0000-0003-0833-6927
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID https://orcid.org/0000-0001-5558-3547
Sean PitrodaDepartment of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL, USA.ORCID https://orcid.org/0000-0003-3056-7991
Sergio A QuezadaCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.ORCID https://orcid.org/0000-0002-9763-1700
Laura SantambrogioDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-4674-7041
Stephen ShiaoDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0001-7586-2885
John StaggCentre de Recherche du Centre Hospitalier de l'Universite de Montreal, Faculty of Pharmacy, Montreal, Canada.ORCID https://orcid.org/0000-0001-7833-4228
Irma TelarovicLaboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-1657-4650
Robert TimmermanDepartments of Radiation Oncology and Neurosurgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID https://orcid.org/0000-0003-2462-1007
Marie-Catherine VozeninLaboratory of Radiation Oncology, Radiation Oncology Service, Department of Oncology, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-2109-8073
Ralph WeichselbaumDepartment of Radiation and Cellular Oncology, Ludwig Center for Metastases Research, University of Chicago, IL, USA.ORCID https://orcid.org/0000-0002-5643-8939
James WelshThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anna WilkinsDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, Sutton, UK.ORCID https://orcid.org/0000-0002-0425-584X
Chris XuSchool of Applied and Engineering Physics, Cornell University, Ithaca, NY, USA.ORCID https://orcid.org/0000-0002-3493-6427
Roberta ZappasodiDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-7031-6671
Weiping ZouDepartments of Surgery and Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0001-7952-3549
Alexandre BobardGustave Roussy Cancer Campus, Villejuif, France.
Sandra DemariaDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Lorenzo GalluzziDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0003-2257-8500
Eric DeutschDepartment of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Silvia C FormentiDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-8227-8924
Funding
Definition of Immune Infiltrate Phenotype and DNA Damage Response Deficits Across Diverse Murine Mammary CarcinomasR01CA239235 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARCELLOS-HOFF, MARY HELEN · 2019 to 2023
$2.5MInvestigating the Genesis of Tumor Immune Microenvironment (TIME) as a function of InflammationR01CA270332 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary Helen Barcellos-Hoff · 2023 to 2026
$2.2MCancer Research UK 17796Cancer Research UK 28724NCI NIH HHS R01 CA239235NCI NIH HHS R01 CA270332
Abstract
Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.
Indexed as
NeoplasmsCombined Modality TherapyHumansImmunotherapydose and fractionationFLASH radiotherapyimmune checkpoint inhibitorsimmunomodulatorslymph node sparingtumor-associated macrophages
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.